Don't get left behind! The modernized is coming. Check it out now.
Say goodbye to!
The new site is coming soon - go to the modernized
Working… Menu
Trial record 1 of 1 for:    NCT04806854
Previous Study | Return to List | Next Study

PK and PD Study of LUM-201 in Children With Idiopathic Growth Hormone Deficiency: (OraGrowtH212) (OraGrowtH212)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT04806854
Recruitment Status : Active, not recruiting
First Posted : March 19, 2021
Last Update Posted : May 25, 2023
Information provided by (Responsible Party):
Lumos Pharma

Brief Summary:
The goals of this single site trial are to study the pharmacokinetics (PK) and pharmacodynamics of LUM-201 and effects of LUM-201 administration on growth hormone release over time in children with idiopathic pediatric growth hormone deficiency (PGHD).

Condition or disease Intervention/treatment Phase
Growth Hormone Deficiency Drug: LUM-201 Phase 2

Detailed Description:

This trial will have a single screening visit to assess if subjects are eligible to start study therapy. Once subjects have completed screening, and if they are determined to be eligible, they will return to the clinic for a 12-hour pulsatility study. On Day Two of the trial, subjects will be randomized to receive one of two oral daily doses of LUM-201 and PK samples will be collected. All subjects will have an equal chance of being placed in either of the two groups.

The trial consists of treatment until subjects achieve near adult height. After screening, subjects will return to the clinic monthly for the first 6 visits and every three months thereafter. At most clinic visits, subjects will have a physical exam, blood and urine collections. At the Month 6 visit subjects will repeat the 12-hour pulsatility and PK studies.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 24 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Single-Center, Randomized, Open-Label, Parallel Arm Study of Daily Oral LUM-201 in Naive-to-Treatment, Prepubertal Children With Idiopathic Pediatric Growth Hormone Deficiency (PGHD)
Actual Study Start Date : July 14, 2021
Estimated Primary Completion Date : June 2023
Estimated Study Completion Date : July 2030

Arm Intervention/treatment
Experimental: LUM-201 (1.6 mg/kg/day) Drug: LUM-201
Administered orally once daily

Experimental: LUM-201 (3.2 mg/kg/day) Drug: LUM-201
Administered orally once daily

Primary Outcome Measures :
  1. Evaluation of Augmented Growth Hormone (GH) Pulsatility [ Time Frame: Day 1 to Month 6 ]
    12-hour mean GH concentration

  2. Pharmacokinetics of LUM-201 and M8 [ Time Frame: Day 1 to Month 6 ]
    Plasma concentrations (Cmax/Steady State)

Secondary Outcome Measures :
  1. Incidence of adverse events in children with idiopathic GHD [ Time Frame: up to 8 years ]
    Number of events

  2. Height standard deviation score (SDS) [ Time Frame: Day 1 to Month 12 ]
    Change in HT-SDS from Baseline to Month 6 and Month 12

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   4 Years to 9 Years   (Child)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Have a chronological age ≥ 4.0 years and ≤ 10.0 years for girls and ≤ 12.0 years for boys.
  • Have a minimum body weight of 16 kg at the time of screening.
  • Have a bone age examination at screening or within the 6 months prior to screening that is delayed with respect to chronological age. Bone age should be based on the apparent BA of the proximal and distal phalanges, as opposed to the metacarpals, carpals and distal forearm. A central BA reader will make the final determination on BA eligibility.
  • Have HT-SDS ≤ -2.0 or a HT-SDS ≥ 2 SD below mean parental HT-SDS. If the other data (slow HV, low IGF-1, peak GH < 10, and 6-month BA delay) are all consistent with idiopathic GHD, the subject may be enrolled with a height SDS > -2.0 after consultation with the MMs.
  • Have an accurate baseline height velocity ≤ 5.5 cm/year based on at least 6-months of growth, if available
  • Within the past 6 months have a maximal GH response > 3 and < 10 ng/mL from at least one prior GH stimulation test within the past 6 months
  • Have prepubertal status as evidenced by Tanner Stage I breast development in girls and testicular volume < 4.0 mL in boys.
  • Have an arm span to height ratio > 96.5%
  • In girls, have genetic testing results to rule out Turner syndrome. If SHOX genetic testing results are available, they need to be negative.
  • Have normal thyroid function. Subjects diagnosed with hypothyroidism must have documented successful treatment for at least 30 days prior to the Baseline visit.

Exclusion Criteria:

  • Any medical or genetic condition which, in the opinion of the PI or Medical Monitor (MM), can be an independent cause of short stature and/or limit the response to exogenous growth factor treatment (e.g., diabetes, , idiopathic short stature (ISS), SHOX-deficiency, skeletal dysplasia, constitutional growth delay, SGA, other).
  • A medical or genetic condition that, in the opinion of the PI and/or MM, adds unwarranted risk to use of LUM-201 (e.g., scoliosis).
  • Use of any medication that, in the opinion of the PI and/or MM, can independently cause short stature or limit the response to exogenous growth factors (e.g., glucocorticoids).
  • Evidence or history of an intracranial mass (e.g., pituitary tumor, craniopharyngioma).
  • Prior treatment with growth factors including, but not limited to, GH, IGF-1, and GH secretagogues. (These may be used for limited times as a diagnostic test.)
  • Suspicion of absence of pituitary function as evidenced by a maximal stimulated GH ≤ 3 ng/mL or pituitary hormone deficiencies beyond GH and thyroid function or a diagnosis of Organic PGHD.
  • At birth, gestational age < 36.0 weeks.
  • Participation in any therapeutic trial of investigational drug(s) within the prior 6 months.
  • History of spinal, cranial or total body irradiation.
  • Recent commencement of non-stimulant therapy to treat attention deficit hyperactivity disorder (ADHD).

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT04806854

Layout table for location information
Institute of Maternal and Child Research, University of Chile
Santiago, Chile
Sponsors and Collaborators
Lumos Pharma
Layout table for additonal information
Responsible Party: Lumos Pharma Identifier: NCT04806854    
Other Study ID Numbers: LUM-201-03
First Posted: March 19, 2021    Key Record Dates
Last Update Posted: May 25, 2023
Last Verified: May 2023
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Product Manufactured in and Exported from the U.S.: Yes
Keywords provided by Lumos Pharma:
GHD, PGHD, LUM-201, growth hormone secretagogue, height, catch-up growth, pulsatility, pharmacokinetics, pharmacodynamics, PK, PD, idiopathic
Additional relevant MeSH terms:
Layout table for MeSH terms
Dwarfism, Pituitary
Endocrine System Diseases
Bone Diseases, Developmental
Bone Diseases
Musculoskeletal Diseases
Bone Diseases, Endocrine
Pituitary Diseases
Hypothalamic Diseases
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases